- Aspira Women’s Health ( NASDAQ: AWH ) sees preliminary testing volume during the fourth quarter of 2022 of 5,643, an increase of 18 % compared to the fourth quarter of 2021 .
- The number of OvaSuite SM tests performed increased 23% to 21,424 tests during the year ended December 31, 2022, compared to 17,377 tests in 2021.
- The Preliminary results consistent with previously provided cash utilization guidance for the fourth quarter and full year of 2022 .
- The average daily test volume reached a new high in the fourth quarter, increasing to 86.6.
- The company further reduced staff to achieve anticipated year-over-year salary cost savings of about $6 million in 2023 .
For further details see:
Aspira Women's Health reports Q4 preliminary testing volume up 18% Y/Y